Group items tagged

Canada has always had to fight hard to attract talent and investment

MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.

"We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.

nd development of new ideas. It provides not only office and lab space but also free mentoring assistance to new businesses in science, technology and social innovation. While there are probably no chickens hatching at MaRS, it wouldn't be at all surprising to find a company working on, say, a vaccine for bird flu. Approximately 20 incubator companies are currently housed at MaRS, including Clera Inc. - which is developing treatments for schizophrenia and depression; AXS Biomedical Animations Studio - a company that creates 3D medical animation for biomedical research and other applications; and Kanata Chemical Technologies (KCT), which has had great success developing catalysts for the chemical industry (catalysts speed up chemical reactions without being changed or consumed in those reactions

All of the above definitions could apply to the wider innovation community connected with the MaRS Centre. Located in the heart of Toronto's Discovery District - a 2.5 sq. kilometre downtown research district, MaRS is a non-profit environment for the birt

KCT founder and president Kamal Abdur-Rashid came to Canada in 1997 with a degree from the University of the West Indies

For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.

That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.

But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."

Three technology research centres in Ontario Monday said they have agreed to work together to help the province compete more effectively against countries like India and China.

Communitech is working with the Ottawa Centre for Research and Innovation, an economic development corporation located in the nation's capital, and the MaRS Discovery District, a Toronto-based not-for-profit geared towards the commercialization of scientific and technological intellectual property.

MaRS originally stood for Medical and Research Sciences, but has since shied away from that label, said Ross Wallace, director of corporate strategy. The organization doesn't want to be pigeonholed as being just a life sciences or biotechnology outfit -- it lends equal weight to information communications and advanced manufacturing. MaRS may be Toronto-based, but its mandate is province-wide, said Wallace. By joining forces with organizations in other parts of Ontario, MaRS is more likely to fulfill that mandate, he said.

Ross Wallace, director of strategic partnerships at the MarS Centre, which brings together scientists, entrepreneurs and investors, has seen a lot of P3s at their best.

Wallace was as baffled as everybody else. But he believed a business model could be created that would connect medical discoveries coming out of universities and government labs with the money available from private foundations.A year ago, he won one of six fellowships offered by the Walter and Duncan Gordon Foundation to young people eager to tackle global problems. His research led in an unexpected – and welcome – direction. It turned out that he didn't have to invent a new business model. One already existed."I found some really exciting collaboration going on," he said. "A new breed of partnerships had emerged that completely transformed the development and delivery of pharmaceuticals for neglected diseases."

So Wallace redefined his task. He would look for ways to bolster these fledgling P3s.They have a very short history. The first grew out of a program launched by the World Bank in 1999 to pull together money and talent for research on tropical diseases. But it remained buried within the global bureaucracy.

This is Toronto's research district, a maze of concrete and glass where the finest minds collaborate, turning the city into a global centre of biomedical discovery.

Nine research institutes employing 5,000 university faculty members, 2,000 graduate students and 1,100 postdoctoral and clinical fellows lie within a 20-minute walk of each other. This biomedical cluster at the heart of Toronto is one of the largest on the continent, and is one of the 10 largest in the world.

Tom Hudson from Montreal; cell biologist Ben Neel from Boston; and stem-cell biologist Gordon Keller, who came to Toronto in 2006, just months after New York magazine named him one of the scientists that city could not afford to lose. Toronto is also home to Tak Mak, who discovered the "key to the immune system" T-cell receptor, and John Dick, who discovered the first cancer stem cell in 1994 and last year grew a human cancer in a lab mouse for the first time.

Netchange Week taking place at the innovation hub of Toronto – the MaRS Discovery District.

Net Change is Canada’s first week long, city wide event designed to dissolve the divide between digital professionals and social change-makers. With a full five day schedule of sessions helping learn more about leveraging technology to aid awareness of their causes and as a catalyst for social change.

ssues faced by the charity we noticed they shared similar problems that many for-profits and small businesses faced. They had limited marketing resources, need to reach out the people that need their services and increase awareness of the good work they were doing.

U of T’s proposed investment in a medical research-business complex will take the school into another orbit. The first of its kind in Canada, the MaRS (Medical and Related Sciences) Discovery District will include facilities for start-up companies created to develop and market research discoveries. U of T will kick in $5 million for the not-for-profit corporation to be located on College Street, east of University Avenue.

MaRS, a Toronto-based, not-for-profit incubation center, is leading a delegation of five cleantech ventures at this week’s Cleantech Forum XXIII in Boston. The companies – all clients of MaRS advisory services – will showcase their products for the cleantech CEOs, investors, scientists and policy makers attending the east coast forum. “While cleantech is a relatively new sector for MaRS advisory services, it is fast catching up with our other core strengths in information technologies and life sciences,” said Tom Rand, a cleantech entrepreneur, author and investor who leads MaRS’ cleantech practice. “MaRS is establishing itself as a major deal-flow engine in the cleantech sector, with an emphasis on early-stage companies.”

Alternative Fuels

Nimtech

Between June 8-12, 2009, MaRS held our first ever Net Change, a week dedicated to exploring this intersection between social technology and social change.

Fourteen different Net Change events, including an art show, experimented with ways of creating and sharing information and knowledge on this question. Bridging the “digital divide” between web professionals and people creating social change, participants were from all different sectors and leadership levels. T

Net Change also addressed critical concepts such as how to measure the impact of social technology, and what we really mean by social change, while including storytelling to hit theoretical concepts home.